Wednesday 14 October 2026
Export OSCR’s income statement to Excel — free account
Oscar Health, Inc.
OSCR Healthcare Healthcare Plans
Oscar Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.7 billion, up 27.5% from fiscal 2024. In the quarter to June 2026, revenue grew 70.4%, EPS grew 234.8%, free cash flow grew 316.3% and total debt rose 43.9%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
33.79
0.22
−0.65%
Follow OSCR
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 5 | 5 | 5 | 6 | 3 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 79.06 | 0.00 |
Altman Z-Score |
— | — | (0.57) | (0.63) | 0.65 | 1.25 | 1.07 |
P/S ratio |
2.20 | 2.20 | 0.76 | 0.13 | 0.34 | 0.35 | 0.32 |
Altman Z″-Score (non-manufacturers) |
(6.15) | (4.92) | (3.28) | (4.47) | (3.18) | (3.57) | (3.40) |
P/FCF ratio |
4.88 | 4.88 | 0.00 | 1.49 | 0.00 | 3.40 | 3.56 |
P/Operating CF |
11.44 | 11.44 | 40.75 | 3.45 | 6.79 | 9.32 | 5.61 |
Beneish M-Score |
— | (3.61) | 0.30 | (3.24) | (1.84) | (2.75) | (2.18) |
P/B ratio |
0.00 | 0.00 | 1.01 | 0.59 | 2.50 | 3.18 | 3.84 |
Price to Tangible BV |
0.00 | 0.00 | 1.01 | 0.59 | 2.50 | 3.18 | 3.84 |
EV/Sales |
0.72 | 0.72 | 0.24 | (0.19) | 0.08 | 0.22 | 0.12 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 1.29 | 0.00 | 31.64 | 0.00 |
EV/Operating CF |
1.50 | 1.50 | (2.44) | (1.94) | (1.64) | 2.05 | 1.30 |
EV/FCF |
1.60 | 1.60 | (2.14) | (2.10) | (1.50) | 2.11 | 1.35 |
Quick Ratio |
0.41 | 0.58 | 0.72 | 0.57 | 0.90 | 0.56 | 0.70 |
Current Ratio |
0.41 | 0.58 | 0.72 | 0.57 | 0.90 | 0.56 | 0.70 |
Net Debt/EBITDA |
1.30 | 1.76 | 2.12 | 2.21 | 6.73 | (19.39) | 5.92 |
Debt/Assets |
0.00% | 6.27% | 0.00% | 6.58% | 8.30% | 6.19% | 6.80% |
Debt/Equity |
0.00 | 0.32 | 0.00 | 0.33 | 0.37 | 0.29 | 0.44 |
Asset Turnover |
0.39 | 0.26 | 0.66 | 1.01 | 1.44 | 2.17 | 2.10 |
Operating CF/Net income |
0.63 | (0.54) | 0.32 | (0.63) | 1.01 | 38.46 | (2.47) |
Capex/Depreciation |
(103.98) | (0.99) | (1.13) | (1.57) | (12.19) | (4.61) | (49.89) |
Interest Coverage |
— | (114.48) | (115.36) | (26.07) | (9.58) | 2.41 | (22.52) |
| 23.31% | 36.97% | (1,185.16%) | (53.07%) | (31.88%) | 2.79% | (44.38%) | |
| (20.62%) | (22.89%) | (20.47%) | (15.45%) | (6.66%) | 0.60% | (7.94%) | |
ROIC |
(1,161.14%) | 0.00% | (117.94%) | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
48.61% | 65.23% | 127.94% | 46.63% | 152.39% | (1.80%) | 33.19% |
Average Days of Receivables |
41.26 | 76.09 | 35.55 | 24.53 | 15.76 | 15.14 | 15.56 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
22.67% | 36.01% | 14.42% | 31.72% | 24.32% | 19.13% | 17.52% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
6.87% | 7.75% | 4.69% | 2.83% | 2.72% | 1.20% | 0.75% |
Graham Net Nets |
(0.88) | (0.88) | (0.46) | (3.46) | (0.33) | (0.59) | (0.52) |
Graham Number |
0.00 | 117.70 | 0.00 | 0.00 | 0.00 | 4.02 | 0.00 |
Earnings Yield |
(39.95%) | (39.95%) | (42.04%) | (115.85%) | (13.19%) | 1.26% | (10.86%) |
Free Cash Flow Yield |
20.49% | 20.49% | (14.78%) | 67.22% | (14.76%) | 29.41% | 28.07% |
Revenue per Share |
16.94 | 15.82 | 10.27 | 18.65 | 26.45 | 38.18 | 44.60 |
Operating CF per Share |
(5.74) | 7.61 | (1.02) | 1.79 | (1.23) | 4.07 | 4.17 |
Capex per Share |
(0.90) | (0.48) | (0.14) | (0.14) | (0.12) | (0.12) | (0.14) |
Free Cash Flow per Share |
(6.64) | 7.13 | (1.16) | 1.65 | (1.34) | 3.95 | 4.03 |
Cash per Share |
11.68 | 28.24 | 6.17 | 7.34 | 8.44 | 6.35 | 10.57 |
Shareholders Equity per Share |
12.17 | 15.34 | 7.78 | 4.20 | 3.64 | 4.23 | 3.74 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
12.17 | 15.34 | 7.78 | 4.20 | 3.64 | 4.23 | 3.74 |
Free Cash Flow |
(191.37) | 208.71 | (207.63) | 351.34 | (297.74) | 950.30 | 1,058.48 |
Working Capital |
(570.35) | (670.89) | (494.18) | (1,359.99) | (239.58) | (1,480.99) | (1,423.52) |
Capital Expenditures |
(26.00) | (14.02) | (25.88) | (29.01) | (25.58) | (27.90) | (36.37) |
Net Current Asset Value |
(604.47) | (900.28) | (646.06) | (1,809.27) | (671.85) | (1,916.21) | (2,071.81) |
EV/EBIT |
0.00 | 0.00 | 0.00 | 1.25 | 0.00 | 34.98 | 0.00 |
Capex to Sales |
0.05 | 0.03 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.42 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.01 | 0.40 | 0.49 | 0.31 | 0.03 | 0.09 | 0.01 |
Cash ROIC |
(27.85%) | 14.72% | (8.32%) | 12.78% | (10.01%) | 33.42% | 25.29% |
Accounts Receivable Turnover |
6.44 | 6.10 | 13.35 | 17.80 | 22.57 | 28.96 | 26.61 |
Accounts Payable Turnover |
0.32 | 0.24 | 0.96 | 1.32 | 1.67 | 2.55 | 2.48 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
860.23 | 1,880.37 | 399.44 | 354.33 | 185.81 | 168.69 | 171.09 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
75.83 | 75.83 | 137.78 | 222.70 | 259.77 | 316.93 | 439.69 |
Average Payables |
1,277.94 | 1,277.94 | 1,685.47 | 2,481.08 | 2,774.01 | 2,875.97 | 4,042.61 |
Average Assets |
1,266.50 | 1,809.51 | 2,796.88 | 3,924.13 | 4,064.04 | 4,220.99 | 5,582.95 |
Average Common Equity |
(1,120.50) | (1,120.52) | 48.31 | 1,142.46 | 849.26 | 911.27 | 998.58 |
Columns are period end dates